Allogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) SVP Benjamin Machinas Beneski sold 5,488 shares of Allogene Therapeutics stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $1.98, for a total transaction of $10,866.24. Following the completion of the transaction, the senior vice president now directly owns 218,507 shares in the company, valued at approximately $432,643.86. This represents a 2.45 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Allogene Therapeutics Stock Performance
Shares of NASDAQ:ALLO traded down $0.01 on Friday, hitting $1.62. The stock had a trading volume of 10,012,923 shares, compared to its average volume of 3,094,591. Allogene Therapeutics, Inc. has a twelve month low of $1.32 and a twelve month high of $4.63. The firm's 50 day moving average price is $1.89 and its 200-day moving average price is $2.28. The company has a market capitalization of $351.97 million, a price-to-earnings ratio of -1.04 and a beta of 1.02.
Allogene Therapeutics (NASDAQ:ALLO - Get Free Report) last issued its earnings results on Thursday, March 13th. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.06. As a group, sell-side analysts predict that Allogene Therapeutics, Inc. will post -1.28 EPS for the current year.
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in the business. California State Teachers Retirement System raised its holdings in shares of Allogene Therapeutics by 6.0% in the fourth quarter. California State Teachers Retirement System now owns 135,554 shares of the company's stock valued at $289,000 after buying an additional 7,685 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Allogene Therapeutics by 18.2% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 270,559 shares of the company's stock valued at $576,000 after buying an additional 41,753 shares during the last quarter. Two Sigma Advisers LP raised its holdings in shares of Allogene Therapeutics by 12.1% in the fourth quarter. Two Sigma Advisers LP now owns 2,702,200 shares of the company's stock valued at $5,756,000 after buying an additional 291,800 shares during the last quarter. Rafferty Asset Management LLC raised its holdings in shares of Allogene Therapeutics by 15.9% in the fourth quarter. Rafferty Asset Management LLC now owns 367,445 shares of the company's stock valued at $783,000 after buying an additional 50,499 shares during the last quarter. Finally, Raiffeisen Bank International AG bought a new position in shares of Allogene Therapeutics in the fourth quarter valued at about $903,000. 83.63% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
ALLO has been the topic of several research analyst reports. Royal Bank of Canada restated an "outperform" rating and issued a $10.00 price objective on shares of Allogene Therapeutics in a research note on Friday, March 14th. HC Wainwright lowered their price objective on shares of Allogene Therapeutics from $9.00 to $8.00 and set a "buy" rating on the stock in a research note on Wednesday. Canaccord Genuity Group restated a "buy" rating and issued a $14.00 price objective on shares of Allogene Therapeutics in a research note on Friday, March 14th. Finally, Citizens Jmp upgraded shares of Allogene Therapeutics from a "market perform" rating to an "outperform" rating and set a $5.00 price objective on the stock in a research note on Friday, March 14th. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $9.29.
View Our Latest Report on ALLO
Allogene Therapeutics Company Profile
(
Get Free Report)
Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).
Read More
Before you consider Allogene Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Allogene Therapeutics wasn't on the list.
While Allogene Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
